SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 22, 2020
Horizon Therapeutics Public Limited Company
(Exact name of registrant as specified in its charter)
|(State or other jurisdiction|
|Connaught House, 1st Floor, 1 Burlington Road, Dublin 4, D04 C5Y6, Ireland|
|(Address of principal executive offices)|
Registrant’s telephone number, including area code: 011-353-1-772-2100
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Name of each exchange
on which registered
|Ordinary shares, nominal value $0.0001 per share||HZNP||The Nasdaq Global Select Market|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Regulation FD Disclosure.
The Company is providing the following information in response to third-party sources that recently issued TEPEZZA prescription data that is an inaccurate and unreliable indicator of TEPEZZA net sales. The Company is reiterating its full-year 2020 TEPEZZA net sales guidance of more than $800 million, which implies double-digit quarter-over-quarter growth.
Forward Looking Statements
This report contains forward-looking statements, including, but not limited to, statements related to the Company’s financial and operating results, and other statements that are not historical facts. These forward-looking statements are based on Horizon’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the risk that the Company’s actual future financial and operating results may differ from its expectations or goals; the Company’s ability to successfully commercialize and grow net sales from existing medicines, including TEPEZZA; impacts of the COVID-19 pandemic and actions taken to slow its spread; risks related to TEPEZZA supply; risks relating to Horizon’s ability to successfully implement its business strategies; and those risks detailed from time-to-time under the caption “Risk Factors” and elsewhere in the Company’s filings and reports with the SEC. The Company undertakes no duty or obligation to update any forward-looking statements contained in this report as a result of new information.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|Date: December 22, 2020||HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY|
/s/ Paul W. Hoelscher
|Paul W. Hoelscher|
|Executive Vice President, Chief Financial Officer|